Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Sees Significant Decrease in Short Interest

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 196,901 shares, a decrease of 26.5% from the March 15th total of 267,884 shares. Based on an average trading volume of 41,997 shares, the short-interest ratio is currently 4.7 days. Currently, 5.9% of the company’s shares are sold short.

Insider Buying and Selling

In related news, major shareholder Daniel Asher bought 15,540 shares of Ekso Bionics stock in a transaction that occurred on Thursday, February 19th. The shares were acquired at an average cost of $12.30 per share, for a total transaction of $191,142.00. Following the completion of the acquisition, the insider directly owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. The trade was a 6.10% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 6.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Ekso Bionics

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its stake in shares of Ekso Bionics by 68.9% during the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Ekso Bionics in the third quarter worth about $198,000. Virtu Financial LLC purchased a new position in shares of Ekso Bionics in the third quarter worth about $57,000. Shay Capital LLC purchased a new position in shares of Ekso Bionics in the third quarter worth about $67,000. Finally, Consolidated Portfolio Review Corp purchased a new position in shares of Ekso Bionics in the third quarter worth about $333,000. 6.42% of the stock is currently owned by institutional investors.

Ekso Bionics Stock Performance

NASDAQ:EKSO traded up $0.14 during trading hours on Thursday, reaching $10.40. The stock had a trading volume of 22,321 shares, compared to its average volume of 179,667. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.07 and a current ratio of 1.63. Ekso Bionics has a 12-month low of $2.73 and a 12-month high of $13.50. The stock has a market cap of $37.02 million, a P/E ratio of -2.02 and a beta of 0.77. The stock has a 50 day simple moving average of $10.43 and a 200 day simple moving average of $7.52.

Analysts Set New Price Targets

Several brokerages recently commented on EKSO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ekso Bionics in a report on Friday, March 27th. HC Wainwright lowered Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $6.00.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.